Developer docs
API playgroundTry for free, no card

Search company profiles

Lucidome Bio

Full company profile

uuid0002wqf

Namestring
Lucidome Bio
Legal namestring
Lucidome Bio
Websiteurl
lucidomebio.com
Company typeenum
Private
Founded yearint
2024
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWellington, New Zealand
HQ citystring
Wellington
HQ countrystring
New Zealand
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
livestock methane vaccine, ruminant vaccine development, agricultural biotechnology, methane emission reduction, animal health vaccines
Industry4 codes
PRIMARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAKAB
Livestock Vaccines (Cattle, Swine, Sheep & Goats)
SECONDARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAIAEAH
Veterinary Vaccines
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Livestock Vaccines
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Methane-reducing vaccine for livestock
TypeOne Time License
Description

Pre-revenue company in R&D phase. Plans to commercialize a methane-reducing vaccine for ruminant animals. The company aims to get approved vaccines into the hands of farmers within five years, with potential licensing opportunities to global animal health companies.

lucidomebio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lucidome Bio is developing a single methane-reducing vaccine for ruminant livestock (cattle and sheep). The vaccine trains the animal's immune system to produce antibodies in saliva that bind to methane-producing microbes (methanogens) in the rumen, suppressing methanogen growth and reducing methane emissions while maintaining animal health and productivity. The product is currently in R&D with field trials underway, targeting commercial availability within approximately five years.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Antibodies in saliva sufficient to coat all methanogens in the rumen (10,000+ antibody molecules per methanogen cell)
+2 more records
Product overview1 text field

Lucidome Bio is developing a single core product: a methane-reducing vaccine for ruminant livestock (cattle and other grazing animals). The vaccine triggers the animal's immune system to produce antibodies in saliva that suppress methanogens in the rumen, reducing methane emissions while boosting productivity. The company is focused on accelerating development through advanced digital tools including AI-assisted biological modelling, genomic analysis, and bioinformatics to identify and validate vaccine targets. The vaccine is designed to be safe, scalable, and affordable for pasture-based farming systems worldwide.

Product and service1 record
1Methane Reducing Vaccine
CategoryLivestock Vaccines / Veterinary Biologics
Description

A vaccine designed to train the immune system of ruminant animals (cattle, sheep, and other grazing livestock) to produce antibodies in saliva that suppress methane-producing microbes (methanogens) in the rumen. The vaccine targets methanogen surface proteins, reducing methanogen growth and methane emissions without affecting animal health or digestion. It is being developed for pasture-based and mixed farming systems where feed additives are ineffective, with global applicability supported by demonstrated consistency of methanogen populations worldwide.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Critical research partner providing scientific expertise. AgResearch scientists are seconded to Lucidome Bio and provide access to research facilities. The methane vaccine research has been pioneered by AgResearch scientists for over 15 years.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborating on methane vaccine research. Part of international consortium funded by Bezos Earth Fund. Provides expertise in livestock vaccine development alongside Royal Veterinary College.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner collaborating on vaccine development research. Dr Peter Janssen previously held academic position at Department of Microbiology and Immunology.

4University of Wellington
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner that collaborated with AgResearch on testing efficacy of adjuvants for veterinary use.

lucidomebio.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner collaborating on vaccine development research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Part of international consortium with Pirbright Institute and AgResearch funded by Bezos Earth Fund for methane vaccine research.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ArkeaBio is developing a methane-reducing vaccine for cattle and other ruminants, making it the closest direct competitor to Lucidome Bio. Both companies pursue antibody-based vaccine approaches targeting rumen methanogens, addressing the same customer base of livestock producers under climate-driven demand.

TypeDirect peer
Description

Zelp develops methane-mitigation technology for cattle, including wearable devices and feed-related approaches to reduce enteric emissions. It targets the same dairy and beef producers motivated by methane reduction that Lucidome Bio is addressing.

TypeDirect peer
Description

CH4 Global commercializes Asparagopsis seaweed-based feed supplements to reduce enteric methane in cattle. It is a leading direct competitor pursuing a feed-additive pathway to the same methane-reduction outcome, serving beef and dairy producers globally.

TypeDirect peer
Description

Symbrosia uses seaweed (Asparagopsis) as a feed additive to reduce livestock methane emissions. It competes with Lucidome Bio for the same farmer/customer dollars aimed at reducing enteric methane, although via a different technical approach.

TypeEmerging player
Description

Mootral develops feed-additive and natural-product based solutions for enteric methane reduction in cattle. It overlaps with Lucidome Bio's target market (methane-conscious dairy and beef producers) but uses a different technical mechanism.

TypeRegional player
Description

Sea Forest is an Australian company producing Asparagopsis-based feed supplements for livestock methane reduction. It competes in adjacent geographies (primarily Australia) with a similar end-customer value proposition to Lucidome Bio's vaccine.

TypeBroad incumbent
Description

Elanco is a large global animal health company offering vaccines, pharmaceuticals, and sustainability solutions for livestock. It is a potential licensee or strategic partner for Lucidome Bio, given its established global veterinary distribution and growing sustainability portfolio.

TypeBroad incumbent
Description

Zoetis is the world's largest animal health company with deep livestock vaccine and pharmaceutical capabilities. As a broad incumbent, it is a likely candidate for licensing Lucidome Bio's vaccine technology and reaching Lucidome Bio's target customer base globally.

9Boehringer Ingelheim Animal Health
TypeBroad incumbent
Description

Boehringer Ingelheim's animal health division is a global leader in livestock vaccines and therapeutics. It represents a likely strategic/licensing partner for Lucidome Bio, with established channels to deliver novel vaccines to the same ruminant producers Lucidome Bio targets.

TypeBroad incumbent
Description

dsm-firmenich is a major animal nutrition and health company developing feed additives including methane-reduction solutions (e.g., Bovaer/3-NOP). It is comparable to Lucidome Bio as an adjacent incumbent working on enteric methane reduction through a feed-additive route.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lucidome Bio

Livestock Vaccineslucidomebio.com

Lucidome Bio firmographics

Firmographics
Name
Lucidome Bio
Legal name
Lucidome Bio
Website
https://lucidomebio.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Lucidome Bio industry classification

Industry
Product category
Livestock Vaccines
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAKAB
Livestock Vaccines (Cattle, Swine, Sheep & Goats)
SECONDARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAIAEAH
Veterinary Vaccines

Keywords

  • Livestock methane vaccine
  • Ruminant vaccine development
  • Agricultural biotechnology
  • Methane emission reduction
  • Animal health vaccines

Where Lucidome Bio is headquartered

Location

Headquarters

HQ city
Wellington
HQ country
New Zealand
HQ region
Oceania

Offices1 record

Markets served

Lucidome Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Methane-reducing vaccine for livestock: Pre-revenue company in R&D phase. Plans to commercialize a methane-reducing vaccine for ruminant animals. The company aims to get approved vaccines into the hands of farmers within five years, with potential licensing opportunities to global animal health companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Lucidome Bio product offering

Product offering

Core offering

Lucidome Bio is developing a single methane-reducing vaccine for ruminant livestock (cattle and sheep). The vaccine trains the animal's immune system to produce antibodies in saliva that bind to methane-producing microbes (methanogens) in the rumen, suppressing methanogen growth and reducing methane emissions while maintaining animal health and productivity. The product is currently in R&D with field trials underway, targeting commercial availability within approximately five years.

Product overview

Lucidome Bio is developing a single core product: a methane-reducing vaccine for ruminant livestock (cattle and other grazing animals). The vaccine triggers the animal's immune system to produce antibodies in saliva that suppress methanogens in the rumen, reducing methane emissions while boosting productivity. The company is focused on accelerating development through advanced digital tools including AI-assisted biological modelling, genomic analysis, and bioinformatics to identify and validate vaccine targets. The vaccine is designed to be safe, scalable, and affordable for pasture-based farming systems worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • Methane Reducing Vaccine A vaccine designed to train the immune system of ruminant animals (cattle, sheep, and other grazing livestock) to produce antibodies in saliva that suppress methane-producing microbes (methanogens) in the rumen. The vaccine targets methanogen surface proteins, reducing methanogen growth and methane emissions without affecting animal health or digestion. It is being developed for pasture-based and mixed farming systems where feed additives are ineffective, with global applicability supported by demonstrated consistency of methanogen populations worldwide.

Quantifiable outcome

  • Antibodies in saliva sufficient to coat all methanogens in the rumen (10,000+ antibody molecules per methanogen cell)
  • +2 more outcomes

Companies that use Lucidome Bio

Customer profile

Segments1 record

Ideal customer profiles2 records

Lucidome Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Lucidome Bio partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • AgResearchcoreStrategic or Co-development PartnerCritical research partner providing scientific expertise. AgResearch scientists are seconded to Lucidome Bio and provide access to research facilities. The methane vaccine research has been pioneered by AgResearch scientists for over 15 years.
  • The Pirbright InstitutecoreStrategic or Co-development PartnerCollaborating on methane vaccine research. Part of international consortium funded by Bezos Earth Fund. Provides expertise in livestock vaccine development alongside Royal Veterinary College.
  • University of MelbourneminorStrategic or Co-development PartnerAcademic partner collaborating on vaccine development research. Dr Peter Janssen previously held academic position at Department of Microbiology and Immunology.
  • University of WellingtonminorStrategic or Co-development PartnerAcademic partner that collaborated with AgResearch on testing efficacy of adjuvants for veterinary use.
  • University of Technology Sydney (UTS)minorStrategic or Co-development PartnerAcademic partner collaborating on vaccine development research.
  • Royal Veterinary CollegeminorStrategic or Co-development PartnerPart of international consortium with Pirbright Institute and AgResearch funded by Bezos Earth Fund for methane vaccine research.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Lucidome Bio competitors and assessment

Company assessment

Direct peers

  • ArkeaBio: ArkeaBio is developing a methane-reducing vaccine for cattle and other ruminants, making it the closest direct competitor to Lucidome Bio. Both companies pursue antibody-based vaccine approaches targeting rumen methanogens, addressing the same customer base of livestock producers under climate-driven demand.
  • Zelp (Zero Emissions Livestock Project): Zelp develops methane-mitigation technology for cattle, including wearable devices and feed-related approaches to reduce enteric emissions. It targets the same dairy and beef producers motivated by methane reduction that Lucidome Bio is addressing.
  • CH4 Global: CH4 Global commercializes Asparagopsis seaweed-based feed supplements to reduce enteric methane in cattle. It is a leading direct competitor pursuing a feed-additive pathway to the same methane-reduction outcome, serving beef and dairy producers globally.
  • Symbrosia: Symbrosia uses seaweed (Asparagopsis) as a feed additive to reduce livestock methane emissions. It competes with Lucidome Bio for the same farmer/customer dollars aimed at reducing enteric methane, although via a different technical approach.

Emerging players

  • Mootral: Mootral develops feed-additive and natural-product based solutions for enteric methane reduction in cattle. It overlaps with Lucidome Bio's target market (methane-conscious dairy and beef producers) but uses a different technical mechanism.

Regional players

  • Sea Forest: Sea Forest is an Australian company producing Asparagopsis-based feed supplements for livestock methane reduction. It competes in adjacent geographies (primarily Australia) with a similar end-customer value proposition to Lucidome Bio's vaccine.

Broad incumbents

  • Elanco Animal Health: Elanco is a large global animal health company offering vaccines, pharmaceuticals, and sustainability solutions for livestock. It is a potential licensee or strategic partner for Lucidome Bio, given its established global veterinary distribution and growing sustainability portfolio.
  • Zoetis: Zoetis is the world's largest animal health company with deep livestock vaccine and pharmaceutical capabilities. As a broad incumbent, it is a likely candidate for licensing Lucidome Bio's vaccine technology and reaching Lucidome Bio's target customer base globally.
  • Boehringer Ingelheim Animal Health: Boehringer Ingelheim's animal health division is a global leader in livestock vaccines and therapeutics. It represents a likely strategic/licensing partner for Lucidome Bio, with established channels to deliver novel vaccines to the same ruminant producers Lucidome Bio targets.
  • dsm-firmenich: dsm-firmenich is a major animal nutrition and health company developing feed additives including methane-reduction solutions (e.g., Bovaer/3-NOP). It is comparable to Lucidome Bio as an adjacent incumbent working on enteric methane reduction through a feed-additive route.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Lucidome Bio social profiles

Digital presence

Lucidome Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lucidome Bio leadership team

Management profile

Number of profiles

Profiles8 records

Lucidome Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lucidome Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucidome Bio

What does Lucidome Bio do?

Lucidome Bio is developing a single methane-reducing vaccine for ruminant livestock (cattle and sheep). The vaccine trains the animal's immune system to produce antibodies in saliva that bind to methane-producing microbes (methanogens) in the rumen, suppressing methanogen growth and reducing methane emissions while maintaining animal health and productivity. The product is currently in R&D with field trials underway, targeting commercial availability within approximately five years.

Is Lucidome Bio a public or private company?

Lucidome Bio is a private company. It is classified as corporate owned and is currently operating.

When was Lucidome Bio founded?

Lucidome Bio was founded in 2024. It employs 1 to 10 people.

Where is Lucidome Bio based?

Lucidome Bio is headquartered in Wellington, New Zealand, in the Oceania region.

How does Lucidome Bio make money?

One revenue line is on record: methane-reducing vaccine for livestock.

Who are Lucidome Bio's main competitors?

Direct peers on record are ArkeaBio, Zelp (Zero Emissions Livestock Project), CH4 Global and Symbrosia. Mootral is listed as an emerging player. Sea Forest is listed as a regional player. Broad incumbents are Elanco Animal Health, Zoetis, Boehringer Ingelheim Animal Health and dsm-firmenich.

Does Lucidome Bio have an API?

No public API is recorded for Lucidome Bio.

What industry is Lucidome Bio in?

Lucidome Bio's product category is Livestock Vaccines. Its primary akta.pro industry code is HLAMAEAL, Veterinary Vaccines (Biologics), with a secondary code of HLAMAKAB, Livestock Vaccines (Cattle, Swine, Sheep & Goats). Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals